ImmunityBio (US Stocks: IBRX) operates in the Healthcare sector, specifically in the Biotechnology industry. The company has been under the radar of investors due to its negative net income from continuing operations, which stands at a loss of $417.3M, and a net income applicable to common shares at a loss of $416.6M. Despite these figures, the company has seen a change to net income of $29M. The company's operating income also stands at a loss of $351.3M. The stock has a 50-day moving average (MA) of 1.66 and a 200-day MA of 2.44. The stock's 52-week low stands at 1.21. The company's shares short for the prior month were 39.5M, which increased to
41.6M shares short, indicating a short percent of 0.3176 and a short ratio of 16.78. Analysts have given an overall consensus of 'Buy' for the stock, with 2 estimates. The Wall Street target price is 4.5, with the highest estimated target price being
5 and a naive expected forecast value of 4.73. The possible downside price is 0.037, while the possible upside price is
13.46. The valuation real value stands at 3.8. Despite the negative income numbers, the stock's potential cannot be overlooked. While some traders may be overwhelmed by the complexities of the biotechnology sector, it is prudent to evaluate ImmunityBio in the context of current market trends. Despite witnessing an upswing in the economy, it may not be the ideal time for short-term investors to enter the market. The fluctuations in ImmunityBio's stock price largely mirror the broader market movements. The presence of robust fundamental indicators for the company suggests potential short-term price swings for ImmunityBio investors. The next quarterly report is slated for release on November 14, 2023. The stock has been experiencing higher-than-average trading activity.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Immunitybio. In general, sophisticated investors focus on analyzing Immunitybio stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Immunitybio's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of
Immunitybio's intrinsic value. In addition to deriving basic predictive indicators for Immunitybio, many experienced traders also check how macroeconomic factors affect Immunitybio price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of Immunitybio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Immunitybio's Liquidity
Immunitybio
financial leverage refers to using borrowed capital as a funding source to finance Immunitybio ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Immunitybio financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Immunitybio's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Immunitybio's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Immunitybio's total debt and its cash.
Immunitybio Gross Profit
Immunitybio Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Immunitybio previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Immunitybio Gross Profit growth over the last 10 years. Please check Immunitybio's
gross profit and other
fundamental indicators for more details.
Closer look at Immunitybio Standard Deviation
Immunitybio has current Standard Deviation of 8.7. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.
Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility.
A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.
Standard Deviation | = | SQRT(V) |
| = | 8.7 |
Let's now compare Immunitybio Standard Deviation to its closest peers:
| IBRX | 8.696046912996428 |
| RRR | 1.96 |
| SG | 3.36 |
| BTBD | 4.96 |
| INN | 2.48 |
"Buy low, sell high" is a classic investment adage that may be applicable to ImmunityBio (US Stocks: IBRX). The biotechnology company's stock is currently trading significantly below its 52-week high of $7.1, with a 50-day moving average of $1.6579 and a 200-day moving average of $2.4437. Despite a negative net income of $417.3M, indicating substantial losses, the company has a market capitalization of
$2.25B and a Wall Street target price of $4.5, suggesting potential upside. However, investors should be aware of the company's high total debt of
$723.77M and a high probability of bankruptcy at 96.00%. The company's beta of -0.32 also indicates a negative correlation with the market, meaning it could potentially offer a hedge in a market downturn. In conclusion, while ImmunityBio presents potential opportunities, it also carries significant risks that investors should carefully consider. .
Over 3 percent rise for Immunitybio. What does it mean for investors?
ImmunityBio's stock recently saw an increase of over 3 percent, a positive turn of events for investors. This rise, paired with a downside deviation falling to 6.31, indicates a potential decrease in volatility. A lower downside deviation suggests that the stock's returns are less dispersed and more stable, which could signify less risk. This could be an opportune time for investors to consider ImmunityBio, as the company's stock demonstrates signs of stability amidst an upward trend. ImmunityBio is exhibiting above-average volatility over the chosen time horizon. Investors should examine ImmunityBio independently to ensure that their intended
market timing strategies align with expectations about ImmunityBio's volatility. Understanding different
market volatility trends often assists investors in timing the market. The correct use of volatility indicators allows traders to measure ImmunityBio's stock risk against market volatility during both bullish and bearish trends.
The heightened level of volatility that accompanies bear markets can directly affect ImmunityBio's stock price, adding stress to investors as they watch the value of their shares plummet. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices drop. In conclusion, the current price of Immunitybio (USA Stocks: IBRX) may seem misleading, but a closer look at the data reveals potential for growth. The analyst overall consensus is a 'Buy' with one strong buy recommendation and one hold. The analyst target price estimated value is $4.5, which is higher than both the valuation real value of $3.8 and the valuation market value of $3.7. The naive expected forecast value is even higher at $4.73. Moreover, the potential upside price of
$13.46 greatly outweighs the possible downside price of $0.037, suggesting a significant potential for profit. However, it's worth noting that the highest and lowest estimated target prices by analysts are $5 and $4 respectively, indicating a more conservative outlook. Therefore, while the current price may seem low, the data suggests that Immunitybio has a promising future with a potential for substantial returns. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Immunitybio. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com